Previous Article | Next Article 
J Virol, May 1998, p. 3893-3899, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Cellular Protein Binds Vaccinia Virus Late
Promoters and Activates Transcription In Vitro
Min
Zhu,
Trisha
Moore, and
Steven S.
Broyles*
Department of Biochemistry, Purdue
University, West Lafayette, Indiana 47907
Received 22 September 1997/Accepted 26 January 1998
 |
ABSTRACT |
Available evidence indicates that the transcription of the late
class of vaccinia virus genes requires the participation of several
virus-encoded proteins in addition to the viral RNA polymerase. In this
report we describe the identification of a protein present in extracts
of uninfected HeLa cells that binds avidly to viral late promoter DNA.
The protein bound specifically to several different vaccinia virus late
promoters but not an early nor an intermediate promoter. DNase I
footprinting localized the protein's binding site to nucleotides
surrounding the transcriptional start site of the I1L promoter. Optimal
promoter binding required sequences in the highly conserved TAAAT motif
at the transcriptional start site as well as sequences immediately
upstream; however, one variation on the motif's sequence did not
affect promoter binding by the protein. Partially purified late
promoter binding protein (LPBP) was capable of stimulating the
transcription activity of extracts depleted of LPBP on a late
promoter-driven template, establishing LPBP as a transcription
activator in vitro. These results suggest that a cellular protein is
responsible for targeting vaccinia virus late promoters for initiation
of transcription.
 |
INTRODUCTION |
Vaccinia virus is a member of the
poxvirus family, whose members characteristically have a large DNA
genome and replicate in the cytoplasmic compartment of the cell.
Progression through the virus life cycle is orchestrated through
control of the timing of expression of individual gene products
functioning in DNA replication and virus assembly. Generally, proteins
functioning in DNA replication are synthesized early in the infectious
cycle, and those functioning in assembly are made later (reviewed in
reference 13). Vaccinia virus gene expression is regulated primarily at
the level of transcription initiation. All viral mRNAs are believed to
be synthesized by a virus-encoded, multisubunit RNA polymerase which,
despite its complexity, lacks the ability to recognize any of the three
classes of transcription promoters in the viral genome. The initiation of transcription of the early, intermediate, and late gene classes by
the RNA polymerase appears to require separate and nonoverlapping sets
of auxiliary proteins. Early gene transcription appears to require a
single protein, ETF, which targets early promoters as sites of
initiation of mRNA synthesis (1, 11). Intermediate gene
transcription requires three proteins: the viral mRNA capping enzyme
(21), the viral E4L gene product (15), and
another as yet undefined protein that apparently is not virus encoded (16). Five different proteins have been described as being
required for high-level transcription from vaccinia virus late
promoters in vivo and/or in vitro. These include the vaccinia virus A1L (9), A2L (8, 14), G8R (25), and H5R
(10) gene products. A fifth factor, termed VLTF-X
(8), has not been assigned to a vaccinia virus gene. Two
other proteins, the products of the G2R (5) and A18L
(3) genes, have been implicated in elongation and/or
termination of late transcripts. The specific role of any of these
proteins in the transcription of late genes is not known, nor is it
known which, if any, is responsible for targeting late promoters as
sites for initiation of transcription. In this report, we describe a
cellular protein that has high affinity for late promoters and
activates transcription in vitro.
 |
MATERIALS AND METHODS |
Promoter DNAs.
All late promoter DNAs were originally
generated by PCR on viral genomic DNA with Vent DNA polymerase (New
England Biolabs). For the 11-kDa (gene F18R) and I1L promoters. PCR
primers were designed to produce DNA fragments that included
nucleotides
100 to +46, relative to the first A residue in the TAAAT
motif at the start site for transcription. PCR products were ligated
into the SmaI site of plasmid pBluescript II KS(+)
(Stratagene). The sequences of all plasmid inserts were confirmed by
thermal cycle DNA sequencing with a kit (Epicenter Technologies)
according to the manufacturer's instructions. For all promoters except
H1L, probes were constructed by excision at flanking restriction sites and 3' end labeled with the Klenow fragment of DNA polymerase I and an
-32P-labeled deoxynucleoside triphosphate
(18) whose choice was determined by the restriction enzyme
cleavage site. The H1L promoter probe was constructed by PCR with
primers previously labeled at their 5' ends with polynucleotide kinase
and [
32P]ATP. The H1L probe was designed include
nucleotides
80 to +40. The vaccinia virus growth factor gene (C11R)
early promoter DNA (nucleotides
35 to +15, relative to the
transcriptional start site) and the I3L gene intermediate promoter
(nucleotides
35 to +15, relative to the transcriptional start site)
were excised from plasmids pSB63 and pSB104, respectively, and
similarly radiolabeled at their 3' ends. All DNA probes were purified
by polyacrylamide gel electrophoresis.
DNA affinity matrices were constructed with the 11-kDA and I1L promoter
fragments described above. Promoter fragments were released from
plasmids by cleavage with restriction endonucleases at flanking sites
and were tagged with biotin on their 3' ends with the Klenow fragment
of DNA polymerase I and biotin-16-dUTP. Biotinylated DNA was linked to
streptavidin-conjugated paramagnetic beads (Boehringer Mannheim)
according to the manufacturer's instructions.
Cell extracts and protein purification.
HeLa S-3 cells were
grown in suspension culture to a density of 5 × 105/ml in volumes up to 12 liters and were harvested for
extraction. For virus infections, HeLa cells growing in monolayers in
150-cm2 dishes were infected with vaccinia virus western
reserve strain at a ratio of 10 PFU/cell. After virus absorption in 3 ml of medium for 2 h, fresh medium was substituted and the cells
were incubated for 16 h, unless otherwise stated, prior to being
harvested. All further manipulations were conducted at 4°C. Protein
purification was initiated with 2 × 1010 cells. Cell
pellets were resuspended in 40 ml of 10 mM Tris (pH 9.0)-0.5 mM
phenylmethylsulfonyl fluoride and allowed to swell on ice for 30 min.
Cell lysis was completed by Dounce homogenization with a tight-fitting
pestle. Nuclei and cell debris were removed by centrifugation at
12,000 × g for 30 min. The supernatant was mixed with
18 ml of Ni2+-nitrilo-agarose (Ni-agarose; Qiagen) and
incubated with rocking for 3 h. The resin was washed three times
by centrifugation and resuspension in 40 ml of buffer A (150 mM NaCl,
50 mM Tris [pH 8.0], 0.01% Nonidet P-40). A final wash was done with
20 mM imidazole in buffer A. Protein was eluted with two 10-ml washes
with 300 mM imidazole in buffer A.
Ni-agarose-purified protein was mixed with an equal volume of buffer B
(50 mM Tris [pH 8.0], 0.1 mM EDTA, 1 mM dithiothreitol,
0.01%
Nonidet P-40, 10% glycerol) and applied to a 1-ml phosphocellulose
column equilibrated with 0.1 M NaCl in buffer B. After the protein
was
washed with the same solution, promoter binding activity was
eluted
with 0.3 M NaCl in buffer B. The phosphocellulose eluate
was diluted
with 2 volumes of buffer B and mixed with 100 µl of
a late promoter
DNA affinity matrix. The beads were washed with
0.1 M NaCl in buffer B,
and late promoter binding activity was
eluted with 0.3 M NaCl in buffer
B. DNA affinity-purified protein
was layered onto an 11-ml 15 to 35%
glycerol gradient in buffer
B containing 0.2 M NaCl and subjected to
velocity sedimentation
at 40,000 rpm for 48 h in a Beckman SW41
rotor. Fractions were
collected by pumping from the tube bottom. The
late promoter binding
activity was found to sediment at a rate of about
3.8S relative
to sedimentation standards. The protein preparation at
this stage
is best characterized as partially purified, and we were not
able
to assign a particular polypeptide(s) as being responsible for
promoter binding activity.
DNA binding assays.
Late promoter DNA binding was determined
by electrophoretic mobility shift analysis essentially as described
previously (4). A typical binding reaction mixture contained
1 to 2 ng of radiolabeled probe DNA. DNA probes were mixed with
poly(dI-dC) (Pharmacia), where indicated, prior to the addition of
protein. Protein-DNA complexes were resolved by electrophoresis in a
nondenaturing polyacrylamide gel and visualized by autoradiography
(4).
DNase I footprinting experiments were performed with
32P-labeled promoter DNA segments. The DNA was incubated
either alone or
with 100 ng of protein in 50 mM Tris (pH 8.0)-1 mM
MgCl
2 for 30
min at 22°C. DNase I (Worthington
Biochemicals) was added to a
concentration of 8 ng/ml, and incubation
was continued for an
additional 2 min, after which the cleavage
reaction was terminated
by addition of an equal volume of a stop
solution (0.2 M NaCl,
30 mM EDTA, 1% sodium dodecyl sulfate, and 100 µg of glycogen/ml).
DNA cleavage products were extracted with
phenol-chloroform, precipitated
with ethanol, and analyzed on a 6%
polyacrylamide DNA sequencing
gel. Sequence markers were generated by
subjecting the DNA fragments
to a G+A chemical cleavage reaction
(
12).
Reporter gene experiments.
The green fluorescent protein
(GFP) from Aequorea victoria was used as a reporter for I1L
promoter activity. The GFP coding sequences were isolated from plasmid
pEGFP-N1 (Clontech) (6) by PCR with Vent polymerase as
described above. A NdeI restriction site was engineered into
the sequence at the initiation codon, and the fragment was inserted
into the SmaI site of plasmid pBluescript II KS(+).
Double-stranded synthetic oligonucleotides with the indicated sequences
were ligated between the NdeI site and an upstream
ClaI site to generate the final promoter-GFP gene
constructs. Plasmids were purified on Qiagen columns as recommended by
the manufacturer. Ten micrograms of plasmid was transfected by the calcium phosphate precipitation method (18) into
106 HeLa cells that were previously infected with 10 PFU of
vaccinia virus/cell. After 17 h, the cells were harvested by
scraping and lysed by resuspension in 1 mM Tris (pH 9.0) and Dounce
homogenization. Cell debris was removed by sedimentation at 10,000 × g for 20 s, and the supernatant was assayed for
fluorescence at 510 nm upon excitation at 475 nm in a Hitachi F-2000
fluorescence spectrophotometer. Fluorescence values were normalized to
the mass of the protein as determined with Bio-Rad protein reagent,
using bovine serum albumin as a standard.
In vitro transcription reactions.
Cytoplasmic extracts of
108 HeLa cells infected with virus for 16 h were mixed
with 0.2 ml of Ni-agarose and placed on a rocking platform for 1 h
at 4°C. The beads were subjected to a brief centrifugation, and the
supernatant was retained as the "depleted extract." Transcription reactions were conducted in solutions that were essentially identical to those previously described for early gene transcription
(11). The template for transcription was pCFW9, which has
the 11-kDa promoter followed by a 400-nucleotide G-less cassette
(23). The template was mixed with the indicated amounts of
extract, purified promoter binding protein, buffer, and nucleotides,
using [
-32P]UTP as the label, and incubated at 30°C
for 30 min. At that time, 100 U of RNase T1 (Sigma) was added, and the
incubation was resumed for an additional 15 min. The reaction products
were extracted with phenol-chloroform, precipitated with ethanol, and resolved by electrophoresis on a denaturing 4% polyacrylamide gel
(11). The gel was dried and exposed to X-ray film for
autoradiography. Radiolabeled RNA was quantitated with a Packard
InstantImager.
 |
RESULTS |
Detection of a late promoter DNA binding protein in cell
extracts.
During the course of experiments on histidine-tagged
recombinant proteins expressed by vaccinia virus-based expression
systems, we detected a protein with vaccinia virus late promoter
binding activity that bound Ni-agarose. The vaccinia virus 11-kDa (F18R gene) promoter was used initially for binding experiments because it is
a strong late promoter and its sequence requirements for promoter
activity in vivo have been characterized in some detail (2).
The minimal promoter requires less than 20 nucleotides 5' to the
transcriptional start site, with little obvious requirement for
sequences 3' to the start site. To ensure that all required promoter
elements were present, DNA binding probes were designed to encompass
nucleotides
100 to +46, relative to the first A in the TAAAT motif at
the transcriptional start site. Electrophoretic mobility shift analysis
with the 11-kDa promoter DNA demonstrated that protein purified from
cytoplasmic extracts by Ni-agarose chromatography had nonspecific DNA
binding activity, resulting in aggregation of the probe (Fig.
1A, lane 2); however, a discrete protein-DNA complex was observed when binding reactions were conducted in the presence of low concentrations of the nonspecific competitor poly(dI-dC). The complex was resistant to a 1,000-fold excess of the
polymer, suggesting that binding was specific. Subsequent protein
fractionation experiments showed that the protein with promoter binding
activity was distinct from the expressed recombinant proteins (data not
shown) and, indeed, was not dependent on virus infection. Extracts from
uninfected HeLa cells contained levels of promoter binding activity
similar to those of cells infected with virus (Fig. 1B), indicating
that the late promoter binding protein is not virus encoded or virus
induced.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Detection of late promoter binding activity in
Ni-agarose-purified protein. Extracts from vaccinia virus-infected
cells were chromatographed on Ni-agarose and assayed for binding to the
32P-labeled 120-nucleotide 11-kDa promoter probe. Lane 1 contains probe alone; lanes 2 to 7 contain probe plus 200 ng of
protein. Poly(dI-dC) was included in binding reactions at 0 (lane 2),
100 (lane 3), 200 (lane 4), 500 (lane 5), 1,000 (lane 6), and 2,000 ng
(lane 7). Protein-DNA complexes were resolved by electrophoresis in a
native gel and visualized by autoradiography. The location of the major
protein-probe complex is indicated with an arrow. (B)
Ni-agarose-purified protein from uninfected HeLa cells (lane 1) or
vaccinia virus-infected cells (lane 2) was tested for binding to the
11-kDa promoter probe. The major protein-probe complex is indicated
with an arrow.
|
|
To determine whether the late promoter binding activity identified in
uninfected cells and that found in vaccinia virus-infected
cells were
due to the same protein, the protein with late promoter
binding
activity was purified from both uninfected and virus-infected
cells in
parallel as described in Materials and Methods. The two
proteins
behaved identically when chromatographed on Ni-agarose
and
phosphocellulose, after purification by DNA affinity matrix
and
glycerol gradient sedimentation and produced protein-promoter
DNA
complexes with the same mobility in an electrophoretic gel
shift
experiment (Fig.
1B). It was concluded that the late promoter
binding
protein is of cellular origin and is not significantly
altered by virus
infection. All further experiments were conducted
with protein purified
from uninfected cells.
The promoter binding activity of the cellular protein was further
characterized by titration of the protein on the 11-kDa
promoter (Fig.
2). At low concentrations of protein, a
single
complex was observed (complex 1). As the protein concentration
was increased, two additional slower-migrating complexes (complexes
2 and 3) were observed and appeared to accumulate at the expense
of the
faster-moving complex. The level of binding of the three
complexes
together was quantitated, and Scatchard analysis of
the data yielded a
Kd of 3 nM. This number can be considered to
be
an averaged value of the affinity of the three combined complexes.
It
is emphasized that formation of multiple protein-promoter DNA
complexes
appears to be a feature unique to the 11-kDa promoter.
With all other
late promoters tested, a single major complex has
been observed.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 2.
Titration of the 11-kDa promoter with
Ni-agarose-purified protein. 32P-labeled 120-nucleotide
11-kDa promoter DNA was mixed with 0 (lane 1), 100 (lanes 2 and 3), 200 (lane 4), 300 (lane 5), 400 (lane 6), 500 (lane 7), and 600 ng (lane 8)
of protein in the presence of 40 ng of poly(dI-dC). The mobilities of
complexes 1, 2, and 3 are indicated. The reaction corresponding to lane
3 included 1 mM MgCl2 in addition to the standard binding
buffer.
|
|
Specificity of DNA binding.
Late promoters other than the
11-kDa promoter were tested for binding to the cellular protein. The
I1L (19) and H1L (17) genes have been described
as being transcribed from promoters that are uniquely late. The
promoters for both of these genes were found to form complexes with the
cellular protein, at levels similar to that of the 11-kDa promoter
(Fig. 3A). In contrast, the vaccinia
virus growth factor (gene C11R) promoter, a representative early
promoter (20), and the I3L intermediate promoter, a
representative intermediate promoter (22), did not form
detectable complexes with the protein (Fig. 3B).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Promoter specificity for protein binding. (A)
Ni-agarose-purified protein binding to the I1L (lanes 1 and 2) and H1L
(lanes 3 and 4) late promoters. Lanes 1 and 3 contain probe alone, and
lanes 2 and 4 contain probe plus 300 ng of protein. Major protein-DNA
complexes are indicated with arrows. (B) Protein binding to the VGF
early (gene C11R) promoter (lanes 1 and 2) and I3L intermediate
promoter (lanes 3 and 4). Lanes 1 and 3 contain probe alone, and lanes
2 and 4 contain probe plus 300 ng of protein. The brackets indicate the
expected mobilities of protein-DNA complexes with fragments of these
sizes.
|
|
The specificity of DNA binding was also assessed in competition binding
experiments in which the effect of excess nonradiolabeled
DNA fragments
on binding to
32P-labeled 11-kDa promoter was determined.
Excess 11-kDa promoter
DNA predictably reduced binding to the 11-kDa
promoter DNA to
a level that was almost undetectable at an 80-fold
molar excess
(Fig.
4). Challenge of
11-kDa promoter DNA binding with the same
excess of an unrelated but
similarly sized DNA fragment derived
from the polylinker of plasmid
pBluescript II KS(+) had little
effect. Clearly, this protein has
specificity for late promoter
DNA relative to other DNAs tested.
Hereafter we will refer to
the protein as the late promoter binding
protein (LPBP) until
its identity becomes known.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 4.
Competition assay for late promoter binding specificity.
Binding assays were conducted with 100 ng of Ni-agarose-purified
protein and 32P-labeled 120-nucleotide 11-kDa promoter
probe in the presence of 40 ng of poly(dI-dC). As a competitor, 0 (lane
7), 20 (lanes 1 and 4), 40 (lanes 2 and 5), or 80 ng (lanes 3 and 6) of
nonlabeled 120-nucleotide 11-kDa promoter DNA or plasmid DNA was
included in the reaction. Lane 8 is probe alone. The mobilities of
protein-DNA complexes 1 and 2 are indicated.
|
|
Localization of protein binding in a late promoter.
DNase I
footprinting was used to localize the site(s) of interaction of the
LPBP with late promoter DNAs. Initially the 11-kDa promoter was
selected for this purpose, since its ability to support transcription
in vivo was previously characterized by deletion analysis
(2). When complex 1 (as shown in Fig. 3) was analyzed by
DNase I footprinting, no protected sequences were observed, and when
complexes 2 and 3 were analyzed, a general protection of the entire
probe DNA was observed (data not shown). Because the 11-kDa promoter
had the unusual property of forming multiple stable complexes with
LPBP, it seemed likely that this promoter has multiple binding sites
for LPBP, and the identification of the boundaries for any one specific
site might prove difficult. Therefore, the I1L promoter was chosen for
further study. Protection from DNase I cleavage by LPBP was detected on
the template strand extending from nucleotides
8 to +13, relative to
the first A residue in the TAAAT motif at the transcriptional start
site (Fig. 5). On the nontemplate strand,
weak protection at nucleotides
1 to +8 was observed.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
DNase I footprinting of protein bound to the I1L
promoter. I1L promoter 120-nucleotide DNA uniquely labeled on the
template (A) or nontemplate (B) strand was treated with DNase I in the
absence (lanes 1) or presence (lanes 2) of glycerol gradient-purified
LPBP. Cleavage products were resolved on a 6% polyacrylamide DNA
sequencing gel. Lanes 3 contain probe DNA chemically cleaved at purine
residues. The nucleotide sequence of each strand of the I1L promoter is
shown on the right.
|
|
Nucleotide sequences in the I1L promoter required for interactions
with LPBP.
Our understanding of the architecture of vaccinia virus
late promoters remains poor. A thorough mutagenesis study of the
sequences immediately surrounding the transcriptional start sites of
the vaccinia virus 28-kDa promoter and a synthetic promoter identified only the TAAAT motif as important for transcription (7).
Runs of T residues 5' to this motif were implicated in the function of
synthetic promoter constructs, but the promoter elements upstream of
the TAAAT motif have not been precisely defined. The vaccinia virus
11-kDa promoter sequence requirements for transcriptional activity in
vivo have also been characterized. Promoter deletion studies indicated
that deletion of upstream nucleotides to
17, relative to the first A
in the TAAAT motif, permitted high-level transcription activity;
however, further deletion to nucleotide
1 resulted in complete
inactivation of the promoter (2). We have performed a
similar analysis of the I1L promoter. Nucleotides
16 to +13 of the
I1L promoter (referred to here as full length) were linked to the
coding sequence for GFP. Transfection of this construct into vaccinia
virus-infected cells resulted in significant fluorescence of the
reporter protein (Fig. 6B). The DNA
synthesis inhibitor, cytosine arabinoside, inhibited the appearance of
fluorescence (data not shown), consistent with the promoter being a
late class vaccinia virus promoter. Deletion of the I1L promoter to
1
resulted in a decrease in fluorescence to about 10% of that of the
full-length promoter. Further deletion of the promoter to +5, removing
the TAAAT element, did not result in further reduction of expression of
GFP. These results suggest the existence of an important promoter element upstream of the TAAAT motif. These same oligonucleotides were
then tested for their affinity for LPBP in a competition assay in which
binding of LPBP to the full-length I1L promoter was challenged by an
excess of DNA fragments bearing part or all of the I1L promoter. As
expected, full-length promoter I (nucleotides
16 to +13) effectively
competed with itself for binding to LPBP (Fig. 6C). Essentially all
binding activity was lost in the presence of a 100-fold excess of
competitor. Promoter II (nucleotides
1 to +13) was able to partially
compete for binding to LPBP but was estimated to have an approximately
fivefold reduction in affinity relative to that of the full-length
promoter. Promoter III (nucleotides +5 to +13), which lacks the TAAAT
motif, was completely ineffective in competing with promoter I for LPBP
binding. Because deletion to nucleotide
1 partially attenuated
binding and loss of the TAAAT motif resulted in nearly total loss of
binding by LPBP, these results suggest that LPBP requires sequences
both upstream of and within the TAAAT motif in order to interact with
the I1L promoter.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of promoter deletions on activity of the I1L
promoter in vivo and on binding to LPBP. (A) Nucleotide sequences of
promoters bearing the vaccinia virus DNA nucleotides 16 to +13
(promoter I), 1 to +13 (promoter II), or +5 to +13 (promoter III).
Nucleotides are numbered in reference to the first A residue in the
TAAAT motif. The open reading frame encoding GFP begins with the ATG
beginning at nucleotide +17. (B) Fluorescence from cell extracts
resulting from GFP expression driven by promoter constructs I, II, and
III. Solid bars represent fluorescence normalized to the mass of the
protein, and open bars indicate the mean standard deviations of the
values from three experiments. (C) Competition assays for affinity of
LPBP for promoters I, II, and III. 32P-labeled DNA
fragments bearing the sequence of promoter I were exposed to glycerol
gradient-purified LPBP in the presence of a 50- (lanes 1, 3, and 5) or
100-fold (lanes 2, 4, and 6) molar excess of DNA fragments with the
sequence of promoter I (lanes 1 and 2), promoter II (lanes 3 and 4), or
promoter III (lanes 5 and 6). Protein-DNA complexes were resolved by
electrophoretic mobility shift. The arrow at the right indicates the
mobility of the DNA-protein complex. Lane 7 contains LPBP binding in
the absence of a competitor, and lane 8 contains probe alone.
|
|
The most highly conserved feature of vaccinia virus late promoters is
the TAAAT sequence at the site of initiation of transcription.
The
effects of replacement of the nucleotides in this motif vary
among
different late promoters, but the A residues in the motif
appear to be
absolutely essential for transcription activity in
vivo (
7).
Because the binding site for LPBP was localized to
the vicinity of this
sequence in the I1L promoter, it was of interest
to determine whether
the TAAAT sequence is a determinant for binding
by LPBP. To test this
idea, the abilities of DNA segments with
the wild-type 11-kDa promoter
sequence and with a mutant variant
of the 11-kDa promoter to bind to
LPBP were compared. In the mutant
variant, the first three nucleotides
of the TAAAT motif are replaced
with ATT, a change expected to have
severe effects on late promoter
binding in vivo (
7). LPBP
bound both the wild-type and mutant
variant probes to the same extent
(Fig.
7). Because the 11-kDa
promoter
appears to have multiple LPBP binding sites, a promoter
(I1L) with an
apparently single binding site was also examined.
Identical results
were seen when the binding of LPBP to the I1L
promoter and to the
mutant variant of the 11-kDa promoter were
compared (data not shown).

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 7.
An alteration of the TAAAT motif in the 11K promoter
does not affect LPBP binding. Ni-agarose-purified LPBP (100 ng) was
mixed with double-stranded oligonucleotide probe with the sequence of
the 11K promoter (nucleotides 38 to +18) bearing the wild-type TAAAT
motif at the transcriptional start site, or the substituted ATTAT
motif, in the presence of 40 ng of poly(dI-dC). Protein-DNA complexes
were resolved by native polyacrylamide gel electrophoresis. The primary
complexes (labeled 1 and 2) are indicated by the arrows.
|
|
Transcription factor activity of LPBP.
Assigning a functional
significance to promoter binding by LPBP required a demonstration of an
effect on transcription. Because a system for transcription from
vaccinia virus late promoters has yet to be defined, experiments with
purified proteins are not possible. As an alternative, we used an
approach in which extracts from HeLa cells infected with vaccinia virus
were depleted of LPBP by adsorption to Ni-agarose; we then asked
whether purified LPBP could restore transcription activity on a G-less
template driven by the 11-kDa promoter. High concentrations of the
depleted extracts were capable of catalyzing transcription reactions
that were only marginally stimulated by addition of LPBP (Fig.
8). As the concentration of extract added
to the reaction was reduced, there was a concomitant reduction in the
level of transcripts produced. Significantly, purified LPBP was capable
of stimulating the transcription activity of reactions having lower
concentrations of depleted extracts. The presence of LPBP in these
reactions stimulated RNA product formation by an estimated fivefold.
The residual transcription activity of the depleted extracts suggests that the extracts were possibly not completely depleted of LPBP by
exposure to Ni-agarose, and the dependence of transcription reactions
on LPBP was not apparent until the concentration of protein in the
reaction was reduced. We cannot determine the extent of depletion of
LPBP from the extracts because promoter binding cannot be detected in
crude cytoplasmic extracts (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 8.
Transcriptional activation by LPBP. Cytoplasmic extract
from virus-infected cells was depleted of LPBP by adsorption to
Ni-agarose. Transcription reactions with 195 (lanes 1 and 2), 190 (lanes 3 and 4), 180 (lanes 5 and 6), 170 (lanes 7 and 8), or 160 µg
(lanes 9 and 10) of depleted extract (expressed as total protein) were
conducted on a G-less cassette DNA template driven by the 11-kDa
promoter either in the absence (lanes 1, 3, 5, 7, and 9) or presence of
25 (lane 2), 50 (lane 4), 100 (lane 6), 150 (lane 8), or 200 ng (lane
10) of purified LPBP. The 400-nucleotide RNA products (indicated by the
arrow) were resolved by denaturing polyacrylamide gel
electrophoresis.
|
|
 |
DISCUSSION |
During the course of recombinant protein expression studies, we
have detected a protein with vaccinia virus late promoter binding
activity. This protein, LPBP, exhibits high specificity for late
promoters and apparently has little or no affinity for the other two
classes of viral promoters. It has a high affinity for late promoters,
however, with a Kd in the nanomolar range, a
concentration consistent with a function as a promoter DNA binding protein in vivo. LPBP also appears to be a general late promoter binding protein; it has measurable affinities for all late promoters we
have tested, although the specific affinities for various late promoters have been observed to vary considerably (data not shown). Whether the affinity of LPBP for late promoters is a determinant of
promoter strength, as is believed to be the case for the vaccinia virus
early transcription factor, is unknown. The ability of LPBP to
stimulate transcription in vitro supports the case for its functioning
as a bona fide transcription factor.
Deletion of sequences upstream of the TAAAT motif in the I1L promoter
resulted in loss of promoter activity. This is in agreement with a
report from Bertholet et al. on their analysis of the 11-kDa promoter
(2). Deletion of nucleotides upstream of
1 in the I1L
promoter resulted in incomplete impairment of binding of LPBP. Complete
impairment of binding was not achieved until the TAAAT motif was also
deleted. These results indicate that LPBP recognized the I1L promoter
through contacts in and 5' to the TAAAT motif.
The nearly absolute conservation of the TAAAT motif at the start site
for transcription of late genes and the demonstration that this motif
is absolutely essential for late promoter activity (7) are
compelling arguments for a vital function for this sequence. While it
is clear that this site is used to generate the 5' poly(A) leader on
late mRNAs, it is not unreasonable to predict that the TAAAT motif
targets a protein to late promoters as a means to initiate the assembly
of a preinitiation complex. Because the LPBP binding site was localized
to this region in the I1L promoter, the effect of a substitution in the
TAAAT motif was tested for its effect on LPBP binding. While we did not
test the effect of the substitution on I1L promoter activity, it is expected to result in essentially total loss of activity. The A
residues in this motif have been shown in two cases to be absolutely essential for promoter activity in vivo (7). When the first two A residues in the I1L motif were replaced with T residues, no
effect on LPBP binding was observed. We have analyzed the effect of
only one variation on the TAAAT motif with respect to interaction with
LPBP, but it would appear that interaction with this protein is not the
sole function of the TAAAT motif. The basis for the importance of this
motif in vaccinia virus late transcription remains uncertain, and
further characterization of late viral promoter function is clearly
needed.
The finding that LPBP is a cellular protein was unexpected. The
poxvirus mRNA synthesis machinery is generally regarded as a virtually
autonomous system operating through the activities of a number of
virus-encoded proteins. It is clear that LPBP is not virus encoded. It
is readily detected in uninfected cells. There is precedent, however,
for a host protein functioning as a poxvirus transcription factor. The
intermediate promoter-specific factor referred to as VITF-2
(15) has been shown by Rosales et al. (16) to be
present in uninfected cells.
The functional significance behind the vaccinia virus strategy of
adopting a host protein to control the expression of its late genes,
many of which encode highly expressed structural proteins, is unclear.
Late transcription is activated only after genome replication begins
and continues after the genome is highly amplified in the cell. If most
late promoters in most of the amplified genomes are active, then the
protein that targets late promoters would be expected to be required at
high levels in the cell. Perhaps through the utilization of a
preexisting protein that is present in abundance, the virus can ensure
that accumulation of LPBP is not the rate-limiting step in the
activation of late transcription. Conceptually, this is similar to the
situation for early gene transcription, in which the early gene
transcription machinery is preexistent in the viral core, awaiting only
the uncoating process to initiate high-level transcription. Having LPBP
present in the cell prior to activation of late transcription would
suggest that the initiation of DNA synthesis and the ensuing activation of intermediate promoters is the primary control point mediating the
switch from early to late gene transcription.
It is worth noting that several properties exhibited by LPBP are
similar to those of the factor VLTF-X described by Wright and Coroneos
(24). Both proteins have affinity for Ni-agarose, both
behave similarly upon chromatography on phosphocellulose, and both
appear to activate transcription in vitro. VLTF-X is reportedly virus
induced (24), however, and LPBP is present in uninfected
cells. Whether VLTF-X and LPBP are the same protein remains to be
determined.
 |
ACKNOWLEDGMENTS |
This work was supported by an award from the National Institute
of Allergy and Infectious Diseases.
We are grateful to Gunter Kohlhaw and Jonathan LeBowitz for comments on
the manuscript and to Li Ni and Henry Weiner for help with the use of
their fluorescence spectrophotometer.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry, Purdue University, West Lafayette, IN 47907-1153. Phone: (765) 494-0745. Fax: (765) 494-7897. E-mail:
broyles{at}biochem.purdue.edu.
 |
REFERENCES |
| 1.
|
Baldick, C. J., Jr.,
M. C. Cassetti,
N. Harris, and B. Moss.
1994.
Ordered assembly of a functional preinitiation transcription complex, containing vaccinia virus early transcription factor and RNA polymerase, on an immobilized template.
J. Virol.
68:6052-6056[Abstract/Free Full Text].
|
| 2.
|
Bertholet, C.,
P. Stocco,
E. Van Meir, and R. Wittek.
1986.
Functional analysis of the 5' flanking sequence of a vaccinia virus late gene.
EMBO J.
5:1951-1957[Medline].
|
| 3.
|
Black, E. P., and R. C. Condit.
1996.
Phenotypic characterization of mutants in vaccinia virus gene G2R, a putative transcription elongation factor.
J. Virol.
70:47-54[Abstract].
|
| 4.
|
Broyles, S. S.,
L. Yuen,
S. Shuman, and B. Moss.
1988.
Purification of a factor required for transcription of vaccinia virus early genes.
J. Biol. Chem.
263:10754-10760[Abstract/Free Full Text].
|
| 5.
|
Condit, R. C.,
Y. Xiang, and J. I. Lewis.
1996.
Mutation of vaccinia virus gene G2R causes suppression of gene A18R ts mutants: implications for control of transcription.
Virology
220:10-19[Medline].
|
| 6.
|
Cormack, B. P.,
R. H. Valdivia, and S. Falkow.
1996.
FACS-optimized mutants of the green fluorescent protein (GFP).
Gene
173:33-38[Medline].
|
| 7.
|
Davison, A. J., and B. Moss.
1989.
The structure of vaccinia virus late promoters.
J. Mol. Biol.
210:771-784[Medline].
|
| 8.
|
Hubbs, A. E., and C. W. Wright.
1996.
The A2L intermediate gene product is required for in vitro transcription of a vaccinia virus late promoter.
J. Virol.
70:327-331[Abstract].
|
| 9.
|
Keck, J. G.,
G. R. Kovacs, and B. Moss.
1993.
Overexpression, purification, and late transcription factor activity of the 17-kDa protein encoded by the vaccinia virus A1L gene.
J. Virol.
67:5740-5748[Abstract/Free Full Text].
|
| 10.
|
Kovacs, G. R.,
R. Rosales,
J. G. Keck, and B. Moss.
1994.
Modulation of the cascade model for regulation of vaccinia virus gene expression: purification of a prereplicative, late-stage-specific transcription factor.
J. Virol.
68:3443-3447[Abstract/Free Full Text].
|
| 11.
|
Li, J., and S. S. Broyles.
1993.
Recruitment of vaccinia virus RNA polymerase to early gene promoters by the viral early transcription factor.
J. Biol. Chem.
268:2273-2280[Abstract/Free Full Text].
|
| 12.
|
Maxam, A. M., and W. Gilbert.
1977.
A new method for sequencing DNA.
Proc. Natl. Acad. Sci. USA
74:560-564[Abstract/Free Full Text].
|
| 13.
|
Moss, B.
1996.
In
Poxviridae: the viruses and their replication, 3rd ed.
Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 14.
|
Passarelli, A. L.,
G. R. Kovacs, and B. Moss.
1996.
Transcription of a vaccinia virus late promoter template: requirement for the product of the A2L intermediate-stage gene.
J. Virol.
70:4444-4450[Abstract].
|
| 15.
|
Rosales, R.,
N. Harris,
B.-Y. Ahn, and B. Moss.
1994.
Purification and identification of a vaccinia virus-encoded intermediate stage promoter-specific transcription factor that has homology to eukaryotic transcription factor SII(TFIIS) and an additional role as a viral RNA polymerase subunit.
J. Biol. Chem.
269:14260-14267[Abstract/Free Full Text].
|
| 16.
|
Rosales, R.,
G. Sutter, and B. Moss.
1994.
A cellular factor is required for transcription of vaccinia virus intermediate stage genes.
Proc. Natl. Acad. Sci. USA
91:3794-3798[Abstract/Free Full Text].
|
| 17.
|
Rosel, J. L.,
P. L. Earl,
J. P. Weir, and B. Moss.
1986.
Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment.
J. Virol.
60:436-449[Abstract/Free Full Text].
|
| 18.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
In
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 19.
|
Schmitt, J. F. C., and H. G. Stunnenberg.
1988.
Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment.
J. Virol.
62:1889-1897[Abstract/Free Full Text].
|
| 20.
|
Venkatesan, S.,
B. M. Baroudy, and B. Moss.
1981.
Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene.
Cell
25:805-813[Medline].
|
| 21.
|
Vos, J. C.,
M. Sasker, and H. G. Stunnenberg.
1991.
Vaccinia virus capping enzyme is a transcription initiation factor.
EMBO J.
10:2552-2558.
|
| 22.
|
Vos, J. C., and H. G. Stunnenberg.
1988.
Derepression of a novel class of vaccinia virus genes upon DNA replication.
EMBO J.
7:3487-3492[Medline].
|
| 23.
|
Wright, C. F., and B. Moss.
1989.
Identification of factors specific for transcription of the late class of vaccinia virus genes.
J. Virol.
63:4224-4233[Abstract/Free Full Text].
|
| 24.
|
Wright, C. W., and A. M. Coroneos.
1993.
Purification of the late transcription system of vaccinia virus: identification of a novel transcription factor.
J. Virol.
67:7264-7270[Abstract/Free Full Text].
|
| 25.
|
Wright, C. F.,
J. G. Keck,
M. M. Tsai, and B. Moss.
1991.
A transcription factor for expression of vaccinia virus late genes is encoded by an intermediate gene.
J. Virol.
65:3715-3720[Abstract/Free Full Text].
|
J Virol, May 1998, p. 3893-3899, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Knutson, B. A., Oh, J., Broyles, S. S.
(2009). Downregulation of vaccinia virus intermediate and late promoters by host transcription factor YY1. J. Gen. Virol.
90: 1592-1599
[Abstract]
[Full Text]
-
Mohamed, M. R., Niles, E. G.
(2003). UUUUUNU Stimulation of Vaccinia Virus Early Gene Transcription Termination: OLIGONUCLEOTIDE SEQUENCE AND STRUCTURAL REQUIREMENTS FOR STIMULATION OF PREMATURE TERMINATION IN VITRO. J. Biol. Chem.
278: 39534-39541
[Abstract]
[Full Text]
-
Lackner, C. A., Condit, R. C.
(2000). Vaccinia Virus Gene A18R DNA Helicase Is a Transcript Release Factor. J. Biol. Chem.
275: 1485-1494
[Abstract]
[Full Text]
-
Broyles, S. S., Liu, X., Zhu, M., Kremer, M.
(1999). Transcription Factor YY1 Is a Vaccinia Virus Late Promoter Activator. J. Biol. Chem.
274: 35662-35667
[Abstract]
[Full Text]
-
Sanz, P., Moss, B.
(1999). Identification of a transcription factor, encoded by two vaccinia virus early genes, that regulates the intermediate stage of viral gene expression. Proc. Natl. Acad. Sci. USA
96: 2692-2697
[Abstract]
[Full Text]
-
Gunasinghe, S. K., Hubbs, A. E., Wright, C. F.
(1998). A Vaccinia Virus Late Transcription Factor with Biochemical and Molecular Identity to a Human Cellular Protein. J. Biol. Chem.
273: 27524-27530
[Abstract]
[Full Text]
-
Mohamed, M. R., Niles, E. G.
(2000). Interaction between Nucleoside Triphosphate Phosphohydrolase I and the H4L Subunit of the Viral RNA Polymerase Is Required for Vaccinia Virus Early Gene Transcript Release. J. Biol. Chem.
275: 25798-25804
[Abstract]
[Full Text]
-
Mohamed, M. R., Niles, E. G.
(2001). The Viral RNA Polymerase H4L Subunit Is Required for Vaccinia Virus Early Gene Transcription Termination. J. Biol. Chem.
276: 20758-20765
[Abstract]
[Full Text]